ORLEANS, Ontario, June 19, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.
Richard has more than 20 years’ experience in sales and marketing in the pharmaceutical industry from coast to coast. During his career, he has held various business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for various pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships through flexibility and efficiency. In the past 10 years, he was also a board member at the companies for which he worked.
“We’re very proud to add Richard Giguere to our senior management team. His vast experience in the sales and marketing of OTC, natural health products and original medications in the pharmaceutical industry across Canada will help drive the execution of our corporate strategy for our Tetra Natural Health and Tetra Veterinary Health divisions,” says Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.
Richard Giguere’s arrival is perfectly aligned with Tetra Bio-Pharma’s decision to restructure its corporation by commercial markets. While Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization of cannabinoid-based prescription drugs and treatments, Tetra Natural Health will develop and sell cannabinoid-based OTC (self-care) products to leverage the post-legalization market and Tetra Veterinary Health will focus on commercialization of cannabinoid-based products for the pet product market.
“I am honored to be able to play an active role in growing both the Tetra Natural Health and Tetra Veterinary Health divisions,” says Richard Giguere, EVP, Commercial Operations. “Tetra has a sound business model, and there are significant opportunities for us to grow our two commercial divisions. I am committed to making the best business and commercial decisions to accelerate the development of these huge potential markets for our cannabinoid-based products.”
As a result of this senior management change, Anne-Sophie Courtois left the corporation thereby terminating her role as Vice President, Marketing and Communications.
About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
More information at: www.tetrabiopharma.com Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. More information at: www.tetrabiopharma.com
For further information, please contact Tetra Bio-Pharma Inc. Guy Chamberland, Interim Chief Executive Officer Guy@tetrabiopharma.com
For investors information, please contact: investors@tetrabiopharma.com (438) 504-5784
For media information, please contact: Daniel Granger Daniel.granger@acjcommunication.com ACJ Communication O: 1 514 840 7990 M: 1 514 232 1556
